Register for a live webcast-"A New CD38-Directed Antibody for the Treatment of Appropriate Relapsed Refractory Multiple Myeloma Patients"

Immunotherapy Basics in Melanoma

Thursday, January 02, 2020

Mario Sznol, MD, professor of medicine and co-leader of cancer immunology at the Yale Cancer Center, discusses the most important immunotherapy agents in the field of melanoma.


Well at the moment there's really 2 major immunotherapy options in melanoma, maybe 3 if you count T-VEC, although I would say that's used relatively rarely in the clinic. The 2 most important drugs are anti-PD1, which are nivolumab (Opdivo) or pembrolizumab (Keytruda) and the other drug is anti-CTLA4, which is ipilimumab (Yervoy).

Anti-PD1 alone can give you long-term survival (rates) in the range of 40% to 45%. Anti-CTLA4 may add about another 7% to 10%, so that survival rate at 5 years. We tend to use either anti-PD1 alone or the combination of anti-PD1 and ipilimumab in the frontline setting in patients with metastatic melanoma.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Related Videos
By: Hope S. Rugo, MD, FASCO
By: Kathleen Madden, MSN, RN, APHN, AOCNP, FNP-BC
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.